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ABSTRACT 
The analysis of the mutational landscape of cancer, including mutual exclusivity and co-occurrence of              
mutations, has been instrumental in studying the disease. We hypothesized that exploring the interplay              
between co-occurrence, mutual exclusivity, and functional interactions between genes will further           
improve our understanding of the disease and help to uncover new relations between cancer driving               
genes and pathways. To this end, we designed a general framework, ​BeWith​ , for identifying modules               
with different combinations of mutation and interaction patterns. We focused on three different settings of               
the ​BeWith schema: (i) ​BeME-WithFun in which the relations between modules are enriched with mutual               
exclusivity while genes within each module are functionally related; (ii) ​BeME-WithCo which combines             
mutual exclusivity between modules with co-occurrence within modules; and (iii) ​BeCo-WithMEFun           
which ensures co-occurrence between modules while the within module relations combine mutual            
exclusivity and functional interactions. We formulated the ​BeWith framework using Integer Linear            
Programming (ILP), enabling us to find optimally scoring sets of modules. Our results demonstrate the               
utility of ​BeWith​ in providing novel information about mutational patterns, driver genes, and pathways. In               
particular, ​BeME-WithFun helped identify functionally coherent modules that might be relevant for            
cancer progression. In addition to finding previously well-known drivers, the identified modules pointed to              
the importance of MTOR and MED23 genes as well as the interaction between NCOR and NCOA3 in                 
breast cancer. Additionally, an application of the ​BeME-WithCo setting revealed that gene groups differ              
with respect to their vulnerability to different mutagenic processes, and helped us to uncover pairs of                
genes with potentially synergetic effects, including a potential synergy between mutations in TP53 and              
metastasis related DCC gene. Overall, BeWith not only helped us uncover relations between potential              
driver genes and pathways, but also provided additional insights on patterns of the mutational landscape,               
going beyond cancer driving mutations.  
 
 
 
 
  
 
 INTRODUCTION 
The analysis of the mutational landscape of cancer has been instrumental in studying the              
disease and identifying its main drivers and subtypes. In particular, mutual exclusivity of             
mutations in cancer drivers has recently attracted a lot of attention. This relation can help identify                
cancer drivers, cancer-driving pathways, and cancer subtypes ​[1–7]​. Although less studied,           
co-occurrence of mutations has also provided critical information about possible synergistic           
effects between pairs of genes ​[8–10]​. 
Importantly, both properties can arise due to several different reasons, making the            
interpretation of the implied gene-gene relations challenging. Specifically, mutually exclusive          
mutations ​within​ functionally interacting genes may indicate that a mutation in either of the two               
genes dysregulates the same pathway. On the other hand, mutually exclusive mutations might             
also reflect a situation where two genes drive two different cancer types or subtypes. Such               
type-specific mutations are more likely to occur ​between​ genes belonging to different pathways.             
We have previously observed that within cancer type mutual exclusivity is more enriched with              
physically interacting pairs of genes compared to the between cancer types mutual exclusivity             
[3]​. Thus, the presence or absence of interactions between mutually exclusive genes might             
provide hints toward the nature of the mutual exclusivity. In addition, the property of mutual               
exclusivity of mutations is not necessarily limited to cancer drivers, and therefore a proper              
understanding of this property is critical for obtaining a better picture of cancer mutational              
landscape in general and for utilization of mutual exclusivity in cancer driver prediction.  
As with mutual exclusivity, co-occurrence of mutations might emerge due to a number of              
different causes. Perhaps the most important case is when the disabling of two genes              
simultaneously might be beneficial for cancer progression. Examples of such a scenario include             
the co-occurrence of TP53 mutation and Myc amplification ​[9,11] or co-occurring mutations in             
PIK3CA and RAS/KRAS ​[5,8,12]​. Alternatively, co-occurrence of somatic mutations might          
indicate the presence of a common mutagenic process. For example, we observed in the              
previous work that the co-occurrence of TP53 and TTN mutations in breast cancer patients was               
not statistically significant based on a test corrected with the samples’ mutation frequencies,             
although they were found to co-occur using an uncorrected Fisher’s exact test ​[13]​. This              
suggests that the co-occurrence of TP53 and TTN was more likely due to a common mutagenic                
process acting on them rather than a benefit to cancer progression.  
Given the diversity of reasons for observing mutual exclusivity and co-occurrence           
relation, we hypothesised that jointly considering co-occurrence, mutual exclusivity and          
functional interaction relationships will yield a better understanding of the mutational landscape            
of cancer. As a step in this direction our goal was to develop an approach able to identify groups                   
of genes (or gene modules) that show a coherent with genes inside and outside modules. While                
many methods to identify cancer related modules exist, such modules are typically identified by              
focusing on relationships of genes within a module. In particular, there have been several              
previous attempts to combine mutual exclusivity and functional interactions for module           
identification ​[1–3,14]​. However, these methods were primarily focused on finding functional           
modules that include mutually exclusive genes rather than uncovering the relations between            
such modules.  
1 
To address this challenge, we designed a general framework, named ​BeWith​ , for            
identifying modules with different combinations of mutation and interaction patterns. On a high             
level, ​BeWith tackles the following problem: given a set of genes and two types of edge scoring                 
functions (within and between scores), find clusters of genes so that genes within a cluster               
maximize the “within” scores while gene pairs spanning two different clusters maximize the             
“between” scores. We formulated the BeWith module identification problem as an Integer Linear             
Programming (ILP) problem and solved it to optimality. The flexibility of the ILP formulation              
allowed us to include additional constraints such as module connectivity to enhance the module              
discovery process. To our best knowledge, our work is the first to design a ​general framework                
that combines mutual exclusivity, co-occurrence, and functional interactions and that is           
systematically applied to identify sets of modules having both between and within properties. 
 
Figure 1. ​Overview of three settings for which BeWith was applied. (A) The goal of BeME-WithFun is to discover 
modules which have dense functional interactions within the modules while having mutually exclusive mutations with 
genes outside the modules (B) In BeME-WithCo we aim to identify modules which have co-occurring mutations within 
the modules while having mutual exclusivity between the modules (C) In BeCo-WithMEFun, we look for modules of 
functional and mutual exclusivity relations inside with co-occurring mutations between modules. 
 
In this work, we focused on three different settings of the ​BeWith​  framework (Figure 1). 
Setting 1 (BeME-WithFun)​ : Our first setting aims to identify multiple dysregulated pathways            
using functional interaction and mutual exclusivity information (Figure 1A). Different from the            
previous module detection methods, we start with the general assumption that genes that are              
mutually exclusive with some other genes are more likely to be relevant to cancer progression               
whether or not their partners are in the same pathway. Based on this assumption, we identify                
modules that are functionally related within and at the same time show mutual exclusivity              
between the modules. While genes within a module may also be mutually exclusive with each               
other, we do not optimize for within module mutual exclusivity.  
Setting 2 (BeME-WithCo)​ : This setting searches for groups of genes that are co-mutated (within)              
and, at the same time, are mutually exclusive with genes in other groups (Figure 1B). While in                 
this setting we are mostly interested in co-occurrence within modules, mutual exclusivity            
between modules helps us pick the gene groups that are potentially relevant to cancer (as in the                 
first setting). There are two possible explanations for co-occurrence of mutations. First, such             
co-mutations might benefit cancer progression. For example, deficiency in the DNA damage            
repair machinery by itself does not cause cancer but rather makes a cell vulnerable to cancer                
causing mutations. Interestingly, if a co-mutation is indeed beneficial for cancer progression,            
then the mutations in turn might lead to a pattern of mutual exclusivity with other cancer driving                 
mutations as we look for in this setting. Second, co-mutation can arise because a mutational               
process might affect a subset of genes disproportionately. Indeed, cancer patients show            
mutational signatures due to a variety of mutagenic processes such as aging, smoking,             
deficiency of DNA damage process, and APOBEC activity ​[15,16]​. In this context, ensuring             
mutual exclusivity between modules can help separate groups of genes affected by different             
mutagenic processes. In either case, combining co-occurrence within modules and mutual           
exclusivity between modules can lead to a more insightful understanding of the cancer             
2 
mutational landscape. The setting is another novel way of analyzing the patterns of cancer              
mutations, using co-occurrence within modules. 
Setting 3 (BeCo-WithMEFun):​ Our third setting is specifically designed to identify co-occurring            
driver pathways. We seek modules displaying functional and mutual exclusivity relations inside a             
module and co-occurrence between modules (Figure 1C). While Leiserson et al. presented an             
anecdotal example of such co-occurring pair of modules (of two genes in each) in their GBM                
data analysis ​[5]​, such modules are hard to find.  
 
We applied ​BeWith in these three complementary settings to two TCGA datasets:            
somatic mutation profiles in breast cancer (BRCA) and endometrial cancer (UCEC). In the main              
text we focus on the results with the BRCA dataset and defer the results with the UCEC data to                   
Supplementary Material S6.  
  
RESULTS 
 
Method Evaluation 
To validate our method, we computed the significance of the results compared to those obtained               
with 100 randomized instances (Supplementary Materials S2). We evaluated the modules           
obtained in each setting for the objective function value and how well the modules identified               
known driver genes. We stress that BeWith is not specifically targeted toward detecting cancer              
driving genes but rather searching for gene modules that may expose various cancer related              
properties including differences in mutational processes. However the modules are still expected            
to be enriched with cancer related genes. Indeed, we found that our modules significantly              
outperformed the random ones with respect to all measures (Table 1).  
 
 Features  # Known Drivers Driver Enrichment  (Hypergeometric test) 
Objective Function 
Value 
BeME_WithFun 
 
 
Real 14 6.9e-8 57.60 
Random (average) 3.85 0.074 9.92 
Significance <0.01 <0.01 <0.01 
BeMe_WithCo 
 
 
Real 7 2.41e-3 43.79 
Random (average)  2.55 0.17 10.75 
Significance <0.01 0.02 <0.01 
 
BeCo_WithMeFu
n 
 
 
Real 2 0.056 3.07 
Random (average) 0.28 0.60 1.12 
Significance 0.04 <0.01 <0.01 
 
Table 1​. Comparison of the results of three settings of the BeWith schema on real and randomized data. 
Notably, the statistical significance of modules obtained with BeCo_WithMeFun was          
lower than for the modules obtained with other methods. For the list of cancer drivers, we used a                  
combined list from COSMIC Cancer Gene Census ​[18]​ and 138 cancer driver genes from ​[19]​. 
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 Comparison with methods for cancer module discovery 
Our approach is different from most of previous methods for mutated module identification as we               
focus on finding modules with relations both within and between modules. Given differences in              
the objectives, we performed the comparison for the purpose of establishing whether modules             
identified with ​BeME-WithFun have similar enrichment in cancer genes relative to the modules             
uncovered by other methods despite the fact that modules uncovered with ​BeME-WithFun are             
optimised to respect different set of  relations.  
The most comparable approaches are Multi-Dendrix ​[20]​, MEMCover ​[21] and CoMDP ​[10]​.            
These algorithms seek to find multiple functional modules based on mutational patterns,            
enforcing mutual exclusivity relation within modules. Multi-Dendrix and MEMCover identify such           
multiple modules assuming mutations may potentially co-occur between modules but without           
enforcing it ​[20,21]​. CoMDP ​[10] attempted to ensure co-occurrences between the modules.            
Table 2 shows the comparison of our results in BeME-WithFun setting with the modules              
obtained from Multi-Dendrix and MEMCover using BRCA somatic mutation dataset.          
Multi-Dendrix looks for multiple modules by optimizing mutation coverage and mutual exclusivity,            
by which they implicitly aims to ensure functional similarity within the modules. MEMCover             
optimizes mutation coverage while utilizing functional interactions and mutual exclusivity within           
modules. Unlike the previous methods, ​BeME-WithFun insists on mutual exclusivity ​between           
modules while using functional interactions within modules. We set Multi-Dendrix to produce the             
same number of modules as ​BeME-WithFun and the core modules (combining the results with              
the maximum module size varied from 2 to 5) were used for comparison. For MEMCover, we                
obtained modules by setting each patient to be covered at least by 5 mutated genes and then                 
chose the same number of modules as ​BeME-WithFun based on the best coverage. Table 2               
shows that ​BeME-WithFun finds better or comparable modules in terms of cancer driver             
enrichment. As we explicitly enforce functional interactions within modules, the ​BeME-WithFun           
modules are more functionally coherent as expected. 
 
Features #Known Drivers Driver Enrichment (Hypergeometric test) 
Functional Coherence 
(Distance) 
BeME_WithFun 14 6.9e-8 1.03 
Multi-Dendrix 9 1.1e-3 2.52 
MemCover 13 3.63e-7 1.08 
Table 2​. Comparison of module properties obtained with ​BeME-WithFun,​ Multi-Dendrix and MEMCover on             
breast cancer data​. 
 
CoMDP considers the setting similar to BeCo-WithMEFun but their original results with CNV             
data identified co-occurring genes that can be attributed to insertion/deletion events in the same              
locus rather than to co-occurring pathways. With BRCA somatic mutation data and requiring the              
same number of genes as returned by our algorithm, CoMDP produced two modules: (TP53)              
and (TTN, USH2A). These included only one known cancer driver (TP53, p=0.33) compared to              
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two drivers (p=0.056) obtained by BeCo-WithMEFun (Section 3.2.3). Importantly, neither TTN           
nor USH2A significantly co-occur with TP53 after correcting for patient mutation frequencies,            
making these modules hard to interpret. 
 
In summary, although BeWith is designed to identify gene modules with specific mutation             
patterns in cancer rather than to find cancer driving genes, the comparison with module finding               
approaches revealed that BeWith performed well in finding driver genes too.  
 
BeME-WithFun: Functional modules with mutual exclusivity between modules  
In this setting, we search for functionally related groups of genes with potential relevance for               
cancer. In order to ensure that genes within each module are likely to be in the same pathway,                  
we enforce functional edges within modules while penalizing functional interactions of genes            
between different modules. We also reward the edges between modules for mutual exclusivity.             
By applying this setting to TCGA BRCA somatic mutation dataset, we identified seven modules              
(Figure 2A) including many prominent drivers in breast cancer such as TP53, AKT1, CDH1,              
PIK3CA, GATA3, and MAP3K1 (in modules 1, 2, 3 and 6). Notably, most of the mutual                
exclusivity relations between modules we identified are among different pathways (Figure 2B).            1
The results reveal that mutual exclusivity, although commonly sought for within pathways, may             
also frequently occur between pathways. In addition, since BeME-WithFun strictly enforces           
functional interactions within the modules, we obtain functionally coherent modules. In particular,            
TP53 and GATA3 are typically put together into one mutual exclusivity module ​[4,5] even though               
they are only distantly functionally related. Overall, by the method design, the BeME-WithFun             
modules are densely connected (distance=1.03) by functional interactions as compared with an            
average distance of 2.52 for Multi-Dendrix and 1.08 for MEMCover on BRCA mutation dataset.              
The method also allows us to identify less frequently mutated drivers (having weak mutual              
exclusivity signals) such as MTOR, MED23, FOXA1, PIK3R1 benefiting from the combined            
analysis with functional interactions. 
 
Figure 2 ​. (A) Modules uncovered by BeME-WithFun for TCGA breast cancer dataset. Cyan and brown edges                
represent pairs of genes with significant mutually exclusive and co-occurring mutations, respectively. Darker edges              
correspond to lower p-valu ​es and p-values less than or equal to 1e-10 have same darkness. Blac​k edges represent                  
functional interactions. The node sizes of genes reflect the number of mutated samples. (B) WeSME p-values                
between the identified modules. There are many significant mutual exclusivity edges between modules and for some,                
the significance of mutual exclusivity is increased compared to the ones with gene pairs.  
Interestingly, module 7 contains two co-occurring genes: NCOR2 (nuclear co-repressor)          
and NCOA3 (coactivator), with the latter being a well-known cancer driver ​[19]​. TBLR1 is              
another nuclear co-repressor and MED23 is a component of the mediator complex and a              
coactivator involved in regulated transcription. The module was not detected by previous            
methods probably due to the co-occurrence between NCOR2 and NCOA3 as most of previous              
methods enforce mutual exclusivity within modules. 
1 ​Except module 1 and 2, in which the genes are closely related and belong to PIK3CA/AKT1/MTOR pathway. They are                    
split into two groups as we maximize mutual exclusivity between modules and the strong mutual exclusivity between                 
modules outweighed the functional relationships. 
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Although not including known cancer drivers, module 5 contains a cluster of 4 mucins -               
members of a family of large proteins which are components in most gel-like secretions and               
some are involved in signalling. Mucins, most predominantly MUC4, have been associated with             
cancer, typically via abnormal expression ​[22–24]​. However, the source of mutual exclusivity and             
the role of mutations in these genes are still not clear. Both module 4 and 5 contain many long                   
genes and were also identified in the UCEC dataset (see Supplementary Material S6).  
We also examined whether the modules identified by BeME-WithFun are more           
significantly mutually exclusive with other genes as compared to the mutual exclusivity of the              
module’s individual genes. The confidence of mutual exclusivity test is largely limited by the              
number of mutated samples, causing the patterns in rarely mutated genes hard to observe.              
Merging genes in the same module into one supergene , we computed WeSME ​p​ -values             2
between the supergenes and other individual genes, which allowed us to identify many new              
mutually exclusive pairs. For example, module 2 that contains PIK3CA and CDH1 is mutually              
exclusive with several genes implicated in cancer including , MED23, and DCC. The mutual              
exclusivity of these two genes with either PIK3CA or CDH1 was not statistically significant, but is                
statistically significant with the supergene corresponding to module 2. Interestingly, module 5            
(with Mucins) is mutually exclusive with many cancer drivers including PIK3CA, MAP3K1 and             
RUNX1. The list of all statistically significant module-gene pairs where the statistical significance             
of the mutual exclusivity of module-gene pair is higher than mutual exclusivity of the given gene                
with any gene in the module is provided in Supplementary Material S7.  
 
BeME-WithCo: co-occurrence modules that are mutually exclusive with each other 
In order to identify informative co-occurrence modules, we applied BeME-WithCo and obtained            
six modules of genes (Figure 3A). As expected, the analysis of the modules in this setting                
revealed both types of co-occurring modules: modules containing putative cancer drivers with            
synergistic mutations and modules that are likely a result of common mutagenic processes.             
Interestingly, we found some modules with both properties, meaning that the genes in the              
module undergo similar mutational processes but their synergistic roles in cancer were also             
implicated in the literature.  
 
Figure 3. ​(A) Modules uncovered by BeME-WithCo on breast cancer data. Edge color-coding and node size coding                 
are the same as in Figure 2. (B) Decomposition of the observed mutational spectra of modules 1, 3, and 6 into                     
predefined COSMIC signatures of mutational processes identified in breast cancer ​[25] ​. Signature 2 is APOBEC               
related, Signature 3 is associated with failure of DNA double-strand break-repair and also with BRCA1 and BRCA2                 
mutations. Signatures 6 and 26 are associated with defective mismatch repair. The aetiology of signatures 5 and 30 is                   
unknown. 
 
Specifically, we found consistent mutational signatures in modules 1, 3, and 6 (Figure             3
3B; see Supplementary Material S4). Mutational signatures are distinctive patterns in mutational            
spectrum that can reveal the underlying mutation generating processes ​[15,16]​. It is interesting             
2 For the newly created supergene, we define that the supergene has a mutation in a patient if there is any                     
mutated gene in the module for the patient. WeSME p-values were computed for the supergene and all other                  
genes. 
3 ​The remaining modules either did not have sufficient number of observed somatic mutations and/or their mutational                 
spectrum could not be decomposed into signatures with a small error (e.g. due to selection towards specific mutations). 
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to see that different modules have different composition of mutational signatures, which in turn              
implies that genes in different modules are affected by different mutagenic processes. The             
mutual exclusivity between modules in this setting facilitates the partitioning, if present in data.              
Uncovering such relation is important for a proper interpretation of mutual exclusivity which can              
be extended to genes beyond cancer drivers. Note that in this setting we used the               
hypergeometric test for co-occurrence to allow, in particular, detection of modules due to             
undergoing the same mutagenic processes. We also applied the more stringent WeSCO test for              
the identified modules to test whether co-occurrence within modules is likely to be functional              
(see the detailed discussion for three representative modules presented below). 
For module 1, the mutational signatures associated with DNA repair are the dominating             
signatures in this module (Signatures 3, 6, and 26). In addition, both genes in the module (TP53                 
and DCC) are known to be associated with cancer. TP53 is involved in DNA repair, growth                
arrest, and apoptosis. In particular, mutations in TP53 can lead to uncontrolled proliferation and              
invasive growth. ​On the other hand, DCC is suggested to have an anti-metastatic role ​[26]​,               
meaning that DCC may only contribute to cancer in the context of a preexisting condition. We                
conjecture that the mutations in DCC may be contributing to cancer progression for the patients               
with defective mismatch repair and/or impaired TP53 functionality.  
In contrast, module 3 is most strongly enriched with Signature 3, which is known to be                
associated with BRCA1 and BRCA2 germline and somatic mutations. The presence of BRCA2             
in this module is consistent with the finding. Interestingly, the module includes PREX2, which              
has been recently identified as a negative regulator of PTEN in breast cancer ​[27]​. ​In addition,                
the gene has been shown to be not only significantly mutated in human melanomas but also                
relevant for melanoma tumorigenesis ​by a combination of mutations and overexpression ​[28]​.            
However, ​the precise mechanism(s) of action remains unknown. The inclusion of PREX2 in             
cluster with BRCA1/2 mutation pattern might shed some light on possible synergistic interactions             
of this recently proposed driver. 
Different from the above two modules, module 6 contains three long genes including             
MUC16 and TTN. An interesting aspect of this cluster is the presence of APOBEC related               
signature (Signature 2) but no mismatch repair associated signatures. For more discussion of             
this and the remaining modules see Supplementary Material S5.  
 
BeCo-WithMEFun: mutually exclusive modules that are co-occurring with each other 
Complementing the above analyses, we utilized BeCo-WithMEFun to look for modules that            
contain mutually exclusive and functionally related genes with co-occurrence between modules.           
The setting is motivated by the fact that a single mutation may be enough to cause pathway                 
dysregulation (thus mutual exclusivity within a module) and multiple dysregulated pathways are            
required for cancer progression. We identified a pair of such modules: Module 1 with TP53 and                
BRCA2, and Module 2 with DCC (Supplementary Fig S4). 
Both BRCA1 and BRCA2 are known to interact with TP53, and contribute to DNA repair               
and transcriptional regulation in response to DNA damage ​[29,30]​. The activation of TP53 can              
also occur in response to DNA damage amongst other stresses. As discussed in the previous               
section, DCC is believed to have anti-metastatic role and its reduced functionality is might have               
a synergistic effect with other cancer driving events. This observation is consistent with the              
finding in the BeME-WithCo setting, and points to a possible synergy between DCC and              
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broader DNA repair pathway. However, BeCo-WithMEFun did not find larger co-occurring           
modules in neither of the two cancers types. 
 
DISCUSSION 
We introduced the BeWith framework to identify multiple mutated modules displaying specific            
mutation patterns between and within modules. In this work, we considered three settings:             
BeME-WithFun (ensuring mutual exclusivity of mutations between different modules and          
functional similarity of genes within modules), BeME-WithCO (ensuring mutual exclusivity          
between modules and co-occurrence of mutations in genes within modules), and           
BeCo-WithMEFun (ensuring co-occurrence between modules while enforcing mutual exclusivity         
and functional interactions within modules). By utilizing these different settings of within and             
between properties, BeWith revealed complex relations between mutual exclusivity, functional          
interactions, and co-occurrence. In particular, BeME-WithFun identified functionally coherent         
modules containing cancer associated genes, including previously unappreciated modules such          
as the NCOA3/NCOR2 module. Different from most of previous methods focusing on mutual             
exclusivity within modules, our methods enforce mutual exclusivity between modules.          
Interestingly, our modules include many known cancer drivers (more or comparable compared            
to previous methods) while they also exhibit significant mutual exclusivity relationships between            
modules. The BeME-WithCo setting also allowed us to investigate mutated modules in a novel              
way by looking for co-occurring mutations inside a module. This setting was particularly             
insightful in helping us uncover pairs of genes with likely synergetic effects in breast cancer.               
Going beyond cancer driving mutations, the setting provided additional insights into underlying            
mutagenic processes in cancer. Specifically, it revealed that different gene groups might differ             
with respect to their vulnerability to different mutagenic processes. The differences can            
contribute to strong mutual exclusivity signals between modules. Finally, while using           
BeCo-WithMEFun, we have been able to elevate some of the observations obtained by             
BeME-WithCo to the pathway level, the setting did not uncover any larger co-occurring             
functional modules where the members of individual modules are mutually exclusive. The            
observation suggests that after conservative correction in co-mutation test with mutation rates,            
co-occurrence of mutations in two different functional modules appears to be a rather rare              
event.  
Overall, BeWith can be used to uncover relationship between genes, gene groups, and             
pathways that were not accessible to previous methods. Importantly, the BeWith formulation is             
very general and can be used to interrogate other aspects of the mutational landscape by               
exploring different combinations of within-between definitions and constraints with simple          
modifications. 
 
METHODS 
We start by defining the Between-Within module finding (BeWith) problem then formulate it as              
an integer linear program. The optimization problem provides a general framework for identifying             
a set of clusters. By adjusting reward and penalty functions, and some of the constraints we can                 
apply the framework to detect modules occurring in the different settings described above. In              
detail, we are given two weight functions ​between​ (i, j) and ​within​ (i, j) for pairs of genes between                 
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and within modules, respectively. We aim to identify a set of modules which maximizes  between               
weights for gene pairs from different modules while maximizing  within weights inside a module              
simultaneously. The optimization problem is NP-hard (as it generalizes Max Cut), but can be              
solved optimally for current datasets as we demonstrate below. 
 
General ILP Formulation for the Between-Within Module Finding Problem 
 
Let be the target number of modules, let be the maximum number of genes per module, K        M         
and let be the set of genes we consider. We aim to group genes into one of modules,  V                 K  
where the -th cluster includes all unselected genes. Denote . We use the  K )( + 1        K ′ = K + 1     
binary variable to indicate whether gene is in module or otherwise. We  yik      i     k y )( ik = 1   yik = 0    
define to be a between module pair if gene and are in two different modules ji          i   j       k1 k2  
respectively and to be a within module pair if both genes belong to the same1 ≠k )( ≤ k1 2 ≤ K                
module ( ; is an unselected pair otherwise. Additionally, the following integer k )1 ≤ k ≤ K  j i          
binary variables are used to capture different types of pairs:  
 
●  if genes  are in the same module, otherwise.xijk = 1 ,i j 0  
●  if pair  is a between module pair, otherwise.zij = 1 ji 0  
●  if pair is unselected,  otherwise.uij = 1 ji 0  
 
The objective of ILP is defined as:  
 
ax  within(i, j) xM ∑
 
ij
between(i, j) z ij + ∑
 
ij
∑
K
k=1 
 ijk (1) 
 
The constraints (2)-(3) ensure that each gene  belongs to exactly one of the modules and thati  
the module size is bounded by .M   
∑
K+1
k=1
yik = 1 i∀ ∈ V (2)
 
∑
 
i∈V
yik ≤ M k 1, ]∀ ∈ [ K (3) 
 
The set of constraints (4)-(6) ensure that  if both  are selected to module , .xijk = 1 ,i j k 1 ≤ k ≤ K   
xijk ≤ yik ij, ∀k 1, ]∀  ∈ [ K (4) 
xijk ≤ yjk ij, ∀k 1, ]∀  ∈ [ K (5) 
xijk ≥ yik + yjk − 1 ij, ∀k 1, ]∀  ∈ [ K (6) 
 
Similarly, the constraints (7)-(10) ensure the proper assignment of  and .uij zij  
uij ≥ yiK′ ij∀ (7) 
uij ≥ yjK′ ij∀ (8) 
uij ≤ yiK′ + yjK′ ij∀ (9) 
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z
ij = 1 − uij − ∑
K
k=1
x
ijk
ij∀ (10) 
 
In some settings, we also added additional constraints for ensuring that the density of the 
modules is at least :D   
(M )(y ) ( )∑
 
j∈{j |∃ij∈E }′ ′ X
y
jk
≥ D − 1
ik
− 1 +D ∑
 
j∈V
y
jk
− 1 i ∀k 1, ]∀ ∈ V ∈ [ K (11) 
where is a subset of gene pairs depending on the setting. Note that if , the module is E
X
              .5D ≥ 0     
a connected subgraph since for any two non-adjacent vertices, they must have a common              
neighbor. We additionally required in some settings that for each gene in a module, it has at           i        
least some edges in a certain type of subset of edges (e.g., mutual exclusivity or           E
Y
     
co-occurrence) with genes in other modules.  
∑
 
j∈{j |ij∈E }′ ′ Y
z
ij
≥ y
ik
i ∀k 1, ]∀ ∈ V ∈ [ K (12) 
Finally, although all the variables are required to be binary, it is sufficient to     , x , u , zy
ik  ijk  ij  ij          
require the variables to be binary and leave the other variables continuous in   y
ik         , u , zxijk  ij  ij    0, ][ 1
, which makes sure that all the variables in the optimal solution are binary but reduces the                 
running time. To improve the efficiency of the method, we implemented a symmetry breaking              
technique. Symmetry in ILPs not only allows for equivalent solutions but can create multiple              
equivalent subproblems in branch-and-bound trees. These equivalent solutions and equivalent          
subproblems can lead to significant increase in the running time and memory usage of              
branch-and-bound algorithms. We reduced the symmetry in solving our ILPs by adding            
constraints to restrict to feasible solution set. For the details of our solution and its impact on the                  
running time we refer to Supplementary Material S3.  
 
Application of BeWith to TCGA datasets 
 
We applied BeWith in three complementary settings for two TCGA datasets: somatic mutation             
profiles in Breast cancer (BRCA, see results below) and endometrial cancer (UCEC, see             
Supplementary Material S6).  
With somatic mutation profiles of 665 BRCA samples (after removing ultra mutated            
samples), we first computed their mutual exclusivity and co-occurring relationships for each            
gene pair and constructed networks retaining only significant relationships. To this end, we used              
WeSME and WeSCO, which are efficient, weighted sampling based methods for testing            
mutually exclusivity and co-occurrence respectively, taking into account mutation frequencies of           
cancer samples ​[13]​. Specifically, we constructed a mutual exclusivity network ,         V , )G
ME
= ( E
ME  
 
in which is a set of gene pairs that have significantly mutually exclusive mutations based on  E
ME
              
WeSME. A co-occurrence network was computed with a hypergeometric test or    V , )G
CO
= ( E
CO  
        
a WeSCO test depending on the setting. In addition, we utilized functional interaction information              
in some settings, obtained from the STRING database ​[17]​.  
The weights , and for each pair are defined based on the protein  (ij)w
F
(ij)w
ME
 (ij)w
CO
          
functional interaction confidence scores, and ​p​ -values from mutual exclusivity test and           
co-occurrence test, respectively. The weights are set to be 0 if the edge does not exist. In the                  
three BeWith settings we used different definitions of between and within functions, and slightly              
10 
different variants of the constraints. See Supplementary Material S2 for details on the scoring              
functions and parameters.  
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S1 Details of different settings for BeWith 
 
S1.1 BeME-WithFun  
This setting searches for functionally related groups of genes with potential relevance for cancer. In               
order to ensure that genes within each module are likely to be in the same pathway, we enforce                  
functional edges within modules while penalizing functional interactions of genes from different            
modules. We also reward mutual exclusivity within a module so our optimization function is:  
         ax  w (ij)xM ∑
 
ij∈E
U
∑
K
k=1 
F ijk
+ ∑
 
ij∈E
U 
 w (ij) (ij)( ME − wF ) zij   
To strengthen the functional relationships among genes of the same module, we utilize the constraints               
(11) to ensure that each module is dense in the functional interaction network. In addition, we                
additionally required that for each gene in a module, it has at least some mutual exclusivity edge(s)      i             
with genes in other modules as in constraints (12) by setting = .EY EME  
∑
 
j∈{j |ij∈E }′ ′ ME
zij ≥ yik i ∀k 1, ]∀ ∈ V ∈ [ K  
 
S1.2 BeME-WithCo  
In order to identify co-occurring modules, we perform BeWith enforcing the co-occurrence within a              
module but penalizing within module mutual exclusivity ( ). To capture       ithin(i, j) (ij) (ij)w  = wCO − wME    
co-occurrence modules that are biologically relevant we reward mutual exclusivity relation between            
modules ( ). The objective function is then defined as follows:etween(i, j) (ij) (ij)b  = wME − wCO  
ax xM ∑
 
ij∈E
U 
 w (ij) (ij)( ME − wCO ) zij + ∑
 
ij∈E
U
∑
K
k=1 
w (ij) (ij)( CO − wME )  ijk  
To strengthen the co-occurrence within each module, we enforce that each module has dense              
co-occurring interactions by the constraints (11). Similarly to BeME-WithFun, we utilize the            
constraints (12) to enforce stronger mutual exclusivity requirement ( = ) among the modules .EY EME  
 
 
S1.3 BeCo-WithMEFun  
Complementing the above analyses we utilized BeWith to look for modules that contain mutually              
exclusive and functionally related genes modules that might co-occur with other modules.            
Specifically, we enforce exclusivity while penalizing co-occurring mutations within modules (          
). Genes in different modules are rewarded forithin(i, j) (ij) (ij) (ij)w  = wME − wCO + wF         
co-occurrence ( ). The objective function is then etween(i, j) (ij) (ij)b  = wCO − w (ij)ME − wF       
defined as: 
ax xM ∑
 
ij∈E
U 
w (ij) (ij) (ij)( CO − wME − wF ) zij + ∑
 
ij∈E
U
∑
K
k=1 
w (ij) (ij) (ij)( ME − wCO + wF )  ijk   
In order to ensure genes within modules are likely to be in the same pathway, we ensure that each                   
module is a dense subnetwork in STRING functional interaction network using the constraints (11). 
To strengthen the co-occurrence between the modules and mutually exclusivity within each module,             
we additionally required that for each gene in a module, it has at least some co-occurrence edge(s)       i            
with genes in other modules ( = ):EY ECO  
∑
 
j∈{j |ij∈E }′ ′ CO
zij ≥ yik i ∀k 1, ]∀ ∈ V ∈ [ K   
 
S2. Data and Parameter Selection 
Processing mutation data: We utilized TCGA BRCA and UCEC somatic mutation datasets. After             
removing ultra mutated samples (> 1000 combined alterations), we obtained 665 BRCA samples and              
207 UCEC samples. For both datasets, we performed WeSME tests for all gene pairs to estimate the                 
significance of mutual exclusivity. WeSME is an efficient, mutation frequency aware testing ​[1] for              
mutual exclusivity. For co-occurrence, we performed both WeSCO and hypergeometric tests           
depending on settings. Similar to WeSME, WeSCO is a mutation frequency aware test for              
co-occurrence. It is more stringent than hypergeometric test and therefore can potentially remove             
some mutational patterns by chance. We used hypergeometric test for BeME-WithCO in which we              
want to identify mutational signature and performed WeSCO analysis for the identified modules. For              
both datasets, we consider genes mutated in at least 7 samples.  
For the BRCA dataset, we retained 174 pairs of genes with from WeSME in all settings. In           .05p ≤ 0        
BeME-WithCo, 1,891 co-occurrent pairs of genes ( , hypergeometric test) were used for      .01p ≤ 0       
further analysis. In BeCo-WithMEFun, we retained 1,235 pairs of genes with WeSCO ( ). For            .05p ≤ 0   
the UCEC dataset, we utilized 280 pairs of genes with from WeSME and 1,028 CO pairs of          .001p ≤ 0         
genes with from hypergeometric tests. To run BeCoWithMEFun on UCEC data, we retain  .001p ≤ 0             
992 pairs of genes with WeSCO . To obtain weights for ME/CO edges, for each significant      .05p ≤ 0           
pairs, we compute the weight of the edge as , which sets the weight at least 1 and         in(− og p, )m l
102
3          
gradually increased when the p-value gets smaller.  
 
Functional interactions: ​To obtain the edge weights for functional interactions, we download            
functional protein interactions from STRING database version 10.0. We use the interactions with high              
confidence scores (>=900), then divided by the maximum (1000) to obtain the functional interaction              
edge weight.  
 
The number of clusters: ​We define as the value of the objective function by setting the number of      (k)f              
modules to . We define as the average module benefit. Starting with and iteratively  k    (k)/kf         k = 2    
1 
increased by 1, we observe that gradually increases but peaks around or then start      (k)/kf       4   5    
decreasing. We pick the number of clusters after is maximized. Figure S1 shows that we stops        (k)/kf          
at for BeME-WithFun, for BeME-WithCo on BRCA dataset, for BeME-WithFun k = 7    k = 6       k = 6    
and BeME-WithCo on UCEC dataset. We used for BeCoWithMEFun with both TCGA k = 5        k = 2       
BRCA and UCEC datasets. 
 
Fig. S1. ​The number of modules  versus average benefit per module  for TCGA BRCA andk (k)/kf  
UCEC datasets. 
 
Density and maximum number of genes per module:​ We set the density of the modules to.7D = 0  
make sure that the majority of genes in the same module are functionally interacting.  For the 
maximum number of genes per module , we set . Note that the maximum number of genes in0M = 1  
our modules on both BRCA and UCEC datasets is less than or equal to 5. 
 
Random instances for method evaluation:​ For each randomized instance, we first randomized the 
STRING functional network by swapping edges, which preserves node degrees. We also permuted the 
p​ -values of mutual exclusivity and co-occurrence tests among all pairs with their p-values <=0.25. 100 
random instances were generated to compute the significance of BeWith modules. 
 
S3 Symmetry Breaking for Solving ILP 
Symmetry in ILPs can lead to significant increase in the running time and memory usage of                
branch-and-bound algorithms because it not only allows for equivalent solutions but can create             
multiple equivalent subproblems in branch-and-bound trees. Previous research have suggested adding           
constraints to restrict to feasible solution set in order to reduce the symmetry in solving ILPs ​[2,3]​. 
A feasible solution to our ILP contains the assignments of the variables which assign gene            yik     
to module . These assignments correspond to a 0-1 matrix where rows represent genes andi    k              
columns represent modules. For example, and represent two feasible solutions when     Y 1   Y 2       
assigning 4 genes to 3 modules. However, and have the same objective value since we can       Y 1   Y 2          
permute the columns of  to obtain .Y 1 Y 2   
 
 
 
To reduce the number of equivalent solutions, we restrict our feasible solutions to assignment              
matrices with columns in increasing lexicographical order. The column/module is         M1   
lexicographically smaller than column if the smallest index of the genes of is less than that of    M2          M1       
. In the above example, has columns in increasing lexicographical order while does not. InM2      Y 2         Y 1    
, column 3 is lexicographically smaller than column 2.Y 1   
We can add the following constraints to the ILP to restrict the feasible region to assignment                
matrices with columns in increasing lexicographical order: 
2 
∑
K
l=k
yil
 
≤ ∑
i−1
j=1
yj(k−1) i ∀k 2, ], i∀ ∈ V ∈ [ K  ≥ k  
The above constraints ensure that we only assign gene to one of the modules         i       , k , ..,k  + 1 . K  
if we already assign one of genes with smaller index to module . Similar constraint sets were            k − 1      
proposed to allocate surgery blocks to operating rooms ​[4]​. 
As shown in Fig. S2, the running time of BeWithCluster is significantly improved when              
adding symmetry breaking constraints for larger . The running time of BeCo-WithMEFun is less      k         
than 10 seconds on both BRCA and UCEC datasets. Furthermore, we found no significant difference               
in results with and without symmetry breaking constraints. 
Fig. S2.​ The running time of BeWithCluster with and without symmetry breaking of BeME-WithFun 
and BeME-WithCo on TCGA BRCA and UCEC datasets. 
S4. Decomposition of Module Mutational Spectrum into Mutational Signatures  
We collected all observed single-nucleotide variants in TCGA together with their immediate sequence             
context for all genes in each module. Mutational spectrum for each module was calculated. We               
decomposed the mutational spectra into predefined mutational signatures using the R package            
deconstructSigs (version: ​1.8.0) ​[5]​. Sanger COSMIC Signatures of Mutational Processes identified in            
breast cancer ​[6] were used for decomposition. The input exome data were normalized to the whole                
genome. Signatures were not extracted for Modules 2, 4, and 5 due to either small number of somatic                  
variants in module genes or large number of presumably selective mutations that lead to increased               
error in decomposition. 
 
S5.  Application of BeWith to TCGA BRCA datasets 
S5.1 Additional information about BeME-WithCo modules  
This section supplements the discussion of modules in Section 3.2.2 BeME-WithCo: co-occurrence            
modules that are mutually exclusive each other in the main text (Figure 3). 
Module 2 includes NCOR2 (nuclear co-repressor) and coactivator (NCOA3), which were also            
included in FU Module 7. Their co-occurrence remain statistically significant with more stringent WeSCO              
test; the mutational spectrum was not decomposed due to small number of somatic mutations in the                
module. This suggests that the co-occurrence is less likely by chance and the mutations may jointly                
contribute to cancer progression. 
Module 6 contains three long genes including MUC16 and TTN, for which recent studies caution               
that the frequent mutations might not necessarily be related to cancer progression even though they are                
often found significantly mutated in cancer ​[7]​. The co-occurrence of TTN and MUC16 is not statistically                
significant when corrected with WeSCO for patient mutation frequency yet their co-occurrences with             
GON4L remain statistically significant (Table S1). An interesting aspect of this cluster is the presence of                
APOBEC related signature (Signature 2) but no mismatch repair associated signatures. This might explain              
the co-occurrence of TTN and MUC16 and their mutual exclusivity with genes in other modules. While                
the mutations in TTN and MUC16 are suspected by many to be the results of mutagenic process rather                  
than synergistic mutations in cancer, it is worth noting that MUC16 as well as GON4L can drive cancer                  
3 
growth when overexpressed ​[8,9]​. While overexpression and mutations can have synergistic effects ​[10]             
and ​GON4L is found overexpressed in 26% of TCGA breast cancers, a mechanistic relation of these                
mutations in cancer progression remains still not clear. 
Finally, we point out that the co-occurrence of gene pairs in modules 4 and 5 is not statistically                  
significant when evaluated with WeSCO and thus is most likely related to sample mutation rates.  
For BeME-WithCo, we used hypergeometric test to estimate the significance of co-occurrence.             
After obtaining the modules, we computed, for every pair of genes in each module, several measures                
of co-mutation including jaccard index and p-value for WeSCO test (Table S1). Unlike             
hypergeometric test, WeSCO corrects for mutation frequency in each sample.  
  gene1 gene2 jaccard index #g1 #g2 hypergeometric WeSCO 
Module 1 DCC TP53 0.041860465 12 212 0.002505756 0.03769 
Module 2 MEF2A NCOR2 0.1875 13 25 2.17E-06 4.20E-05 
Module 2 NCOA3 MEF2A 0.24137931 23 13 3.34E-08 0 
Module 2 NCOA3 NCOR2 0.263157895 23 25 6.52E-10 0 
Module 3 BRCA2 RELN 0.107142857 12 19 0.003706016 0.0158 
Module 3 BRCA2 PREX2 0.142857143 12 12 0.000904382 0.00425 
Module 3 RELN PREX2 0.107142857 19 12 0.003706016 0.0158 
Module 4 PIK3CA MAP2K4 0.072 237 31 0.0076195 0.218 
Module 5 PCDH19 GATA3 0.060240964 13 75 0.009968893 0.0667 
Module 6 GON4L TTN 0.053571429 8 110 0.000382004 0.00485 
Module 6 TTN MUC16 0.12987013 110 64 0.001584299 0.135 
Module 6 GON4L MUC16 0.058823529 8 64 0.004077911 0.022923 
 
Table S1​.Co-occurrence of genes within modules from BeME-WithCo. #g1 (#g2 respectively) is the number of 
samples in which gene1 (or gene2) in the pair has been mutated. 
 
S5.2 Additional information about BeCO-WithMEFun modules  
Fig S3. Modules uncovered by BeCO-WithMEFun for breast cancer TCGA dataset. Edge color-coding and node size                
coding are the same as in Figure 2. 
 
S6. Application of BeWith to TCGA UCEC datasets 
  
S6.1 Evaluation 
 
We evaluated the results with UCEC dataset compared with random instances and Multi-dendrix using              
the same method as with BRCA dataset. 
 
 Features # Known Drivers Driver Enrichment 
(Hypergeometric test) 
Objective Function 
BeME_WithFun 
 
 
Real 10 
5.1e-4 
116.08 
4 
Random (average) 3.75 0.08 15.17 
Significance <0.01 0.03 <0.01 
BeMe_WithCo 
 
 
Real 7 1.48e-3 84.55 
Random (average) 1.56 0.27 13.97 
Significance <0.01 <0.01 <0.01 
 
BeCo_WithMeFun 
 
 
Real 2 0.056 2.36 
Random (average) 0.24 0.61 1.00 
Significance <0.01 <0.01 <0.01 
 
Table S2​. Comparison of the results of the three settings of the BeWith schema on real and randomized UCEC data. 
 
Features # Known Drivers Driver Enrichment 
(Hypergeometric test) 
Functional Coherence 
(Distance) 
BeME_WithFun 10 5.1e-4 1.0 
Multi-Dendrix 10 5.31e-6 2.31 
MEMCover 13 6.25e-8 1.76 
Table S3​. Comparison of the results of BeME-WithFun and Multi-Dendrix (UCEC). 
 
 
S6.2. BeME-WithFun 
By applying this setting to TCGA UCEC somatic mutation dataset, we identified six modules (see               
figure Figure S4) that include key prominent drivers/associated genes in endometrial cancer such as              
TP53, CCND1, KRAS, PTEN, PIK3CA, PIK3R1, RPL22, ARID1A. BeME-WithFun also recovered           
the same TTN and mucin modules as in the case of breast cancer. The emergence of these modules                  
cannot be explained by patient mutation frequency alone as WeSME test take into account the               
mutation frequencies. Surprisingly, we also retrieved a module related to nonsense mediated decay             
(SMG1, SMG7). SMG7 is also known to regulate p53 stability and function in DNA damage stress                
response 
  
Figure S4​. Modules uncovered by BeME-WithFun for endometrial TCGA dataset. Edge color-coding and node size               
coding are the same as in Figure 2.  
 
S6.3 BeME-WithCo 
  
BeME-WithCo retrieved five modules including two one-element modules. Interestingly each of the 
modules contains at least one driver gene (Figure S5). 
 
 
5 
Figure S5​. Modules uncovered by BeME-WithCo for endometrial TCGA dataset. Edge color-coding and node size               
coding are the same as in Figure 2. 
 
S6.4.BeCo-WithMEFun 
 
BeCo-WithMEFun identified ATM gene as being co-mutated with an interacting pair containing            
RPL22 (Ribosomal protein L22) and SMG7 (one of nonsense mediated RNA decay genes). While              
these three genes have been linked to cancer ​[11]​, ​[12]​, ​Kandoth ​[13]​, it remains to be establish                 
whether or not there is a synergistic relation between them. 
 
Figure S6​. Modules uncovered by BeCo-WithMEFun for TCGA UCEC dataset. Edge color-coding and node size               
coding are the same as in Figure 2. 
 
S7. WeSME with BeME-WithFun modules 
In column ​module pv​ , we compute the WeSME p-values between the genes and the corresponding               
modules while the columns ​best pairwise p-value​ contain the smallest WeSME p-values between the               
genes and any genes in the modules. 
 
gene module pv best pairwise p-value 
MED23 4.40E-05 0.000238 
F8 0.000845 0.003535 
FREM2 0.000845 0.003535 
TBL1XR1 0.00199 0.00548 
ATM 0.00215 0.01255 
DNM3 0.00408 0.00922 
STARD8 0.00408 0.00922 
AOAH 0.0079 0.0084 
BRWD3 0.00933 0.01817 
KIF5A 0.00933 0.01817 
LETM1 0.00933 0.01817 
GPR112 0.00933 0.01817 
ADD2 0.00933 0.01817 
TRAPPC8 0.00933 0.01817 
GRIK1 0.00933 0.01817 
ZNF438 0.00933 0.01817 
NUP214 0.00933 0.01817 
MED15 0.00933 0.01817 
DNAH1 0.01 0.0274 
BRCA2 0.01 0.0274 
Table S7.1​ WeSME mutual exclusivity p-values between FU Module 1 (TP53, MTOR, PTEN, AKT1,  
PIK3R1) and other genes 
 
gene module pv best pairwise p-value 
USP36 7.00E-06 2.30E-05 
PEG3 0.000169 0.000425 
UTRN 0.00117 0.00278 
CROCCP2 0.00119 0.00525 
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SPTA1 0.00143 0.0057 
NWD1 0.00195 0.00366 
DDR2 0.00195 0.00366 
HECW2 0.00238 0.00573 
VPS13C 0.002553 0.00573 
DYNC2H1 0.00263 0.00586 
RAB3GAP2 0.00408 0.00739 
VCX3B 0.00408 0.00739 
RBM23 0.00408 0.00739 
DMBT1 0.00408 0.00739 
MAGEC1 0.00408 0.00739 
ITGA1 0.00408 0.00739 
ZDBF2 0.00547 0.0114 
BCORL1 0.00547 0.0114 
NBPF1 0.00676 0.00821 
COL6A5 0.00771 0.017147 
DNAH8 0.0091 0.01776 
DCC 0.0091 0.01776 
ASXL3 0.0091 0.01776 
SMCHD1 0.00975 0.0139 
PRKCQ 0.00975 0.0139 
AP1G2 0.00975 0.0139 
CYP2A13 0.00975 0.0139 
LETM1 0.00975 0.0139 
GPR179 0.00975 0.0139 
TNN 0.00975 0.0139 
C20orf26 0.00975 0.0139 
PARP8 0.00975 0.0139 
MECOM 0.00975 0.0139 
PTCHD2 0.00975 0.0139 
ZNF687 0.00975 0.0139 
TNIK 0.00975 0.0139 
EWSR1 0.00975 0.0139 
MED13 0.00975 0.0139 
STAT4 0.00975 0.0139 
AMPD1 0.00975 0.0139 
Table S7.2​ WeSME mutual exclusivity p-values between FU Module 2 (PIK3CA, CDH1) and other genes 
 
 
gene module pv best pairwise p-value 
ATM 0.0215 0.0341 
GPR98 0.0215 0.0341 
MDN1 0.024 0.0381 
XIRP2 0.024 0.0381 
PTEN 0.0211 0.0406 
MUC4 0.0289 0.0482 
DYNC2H1 0.0401 0.0551 
NEB 0.0354 0.0704 
DMD 0.0354 0.0704 
COL12A1 0.0432 0.0756 
PCNXL2 0.0432 0.0756 
MED23 0.0432 0.0756 
7 
KIAA1109 0.0432 0.0756 
UBR5 0.0432 0.0756 
MUC17 0.0459 0.0822 
Table S7.3​ WeSME mutual exclusivity p-values between FU Module 3 (FOXA, GATA3) and other genes 
 
 
 
gene module pv best pairwise p-value 
MAP3K1 0 0.00003 
GATA3 1.00E-06 0.000067 
DCC 0.00677 0.0297 
NCOA3 0.00718 0.009 
RYR1 0.0122 0.015 
NR1H2 0.0125 0.05165 
CROCCP2 0.0223 0.0249 
F8 0.0239 0.0675 
MGAM 0.0285 0.0878 
FLG 0.0365 0.13 
WDR67 0.0384 0.0867 
NFE2L3 0.0384 0.0867 
RP1L1 0.0384 0.0867 
MEFV 0.0384 0.0867 
HRNR 0.0434 0.112 
Table S7.4​ WeSME mutual exclusivity p-values between FU Module 3 (TTN, DMD, NEB) and other genes 
 
 
gene module pv best pairwise p-value 
MAP3K1 0.000181 0.0213 
PIK3CA 0.000454 0.00451 
GATA3 0.000597 0.00549 
PCDH15 0.00204 0.121 
TSC22D1 0.0105 0.21 
RUNX1 0.0163 0.0319 
FAT2 0.0192 0.121 
TBX3 0.0258 0.179 
LRP1 0.0317 0.162 
TEX15 0.0317 0.162 
ODZ2 0.0317 0.162 
MLLT4 0.0317 0.162 
TG 0.0317 0.162 
CSMD1 0.0371 0.122 
HERC2 0.0391 0.168 
MLL2 0.0391 0.0924 
HCFC1 0.0495 0.178 
ITPR1 0.0495 0.178 
CDC42BPA 0.0495 0.178 
COL14A1 0.0495 0.178 
Table S7.5​ WeSME mutual exclusivity p-values between FU Module 5 (MUC4, MUC16, MUC12, MUC5B) and 
other genes 
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gene module pv best pairwise p-value 
FAT3 0.0381 0.15 
DOCK11 0.0497 0.153 
RB1 0.0497 0.153 
HERC2 0.0497 0.153 
CCDC66 0.0497 0.153 
SHROOM4 0.0497 0.153 
DNAH10 0.0255 0.111 
DNAH3 0.0313 0.101 
PIK3R1 0.0202 0.0843 
PKHD1L1 0.0102 0.0576 
DMD 0.0088 0.0476 
MUC5B 0.0289 0.0662 
HRNR 0.0289 0.0662 
FLG 0.0292 0.059 
RYR2 0.0188 0.0411 
CDH1 0.0493 0.0675 
MUC4 0.0278 0.0336 
MUC16 0.0278 0.0336 
Table S7.6​ WeSME mutual exclusivity p-values between FU Module 6 (MAP3K1, MAP2K4) and other genes 
 
gene module pv best pairwise p-value 
TP53 1.30E-05 0.000282 
MUC12 0.00105 0.0595 
USH2A 0.00419 0.1001 
RYR2 0.0241 0.109 
NEB 0.0368 0.234 
PKHD1L1 0.0377 0.242 
MLL3 0.0437 0.142 
FRG1B 0.044 0.127 
Table S7.7​ WeSME mutual exclusivity p-values between FU Module 7 (NCOR2, NCOA3, MED23, TBL1XR1) 
and other genes 
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